As of Wednesday close, Precision BioSciences Inc.’s (NASDAQ:DTIL) stock was down -$0.01, moving down -1.02 percent to $0.52. The average number of shares traded per day over the past five days has been 2,932,640 shares. 2 times new highs have been achieved over the past 5 days, with a -$0.0148 fall in that time frame. In the last twenty days, the average volume was 1,265,705, while in the previous 50 days, it was 1,026,854.
Since last month, DTIL stock retreated -19.85%. Shares of the company fell to $0.4700 on 08/16/23, the lowest level in the past month. A 52-week high of $2.05 was reached on 01/13/23 after having rallying from a 52-week low of $0.51. Since the beginning of this year, DTIL’s stock price has dropped by -55.88% or -$0.6650, and marked a new high 5 times. However, the stock has declined by -74.39% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
DTIL stock investors should be aware that Precision BioSciences Inc. (DTIL) stock had its last reported insider trading activity 70 days ago on Jun 08. Scimeca Dario, the General Counsel and Secretary of the company, disposed of 13,361 shares for $0.75 on Jun 08. It resulted in a $10,021 divestment by the insider. List Alan sold 7,771 shares at an average price of $0.79 on Apr 27. The insider now owns 56,496 shares following the transaction. On Mar 22, President and CEO Amoroso Michael sold 46,999 shares at $0.82 apiece. The transaction was valued at $38,539.
Valuation Metrics
The stock’s beta is 1.27. Besides these, the trailing price-to-sales (P/S) ratio of 1.31, the price-to-book (PB) ratio of 1.75.
Financial Health
In the three months ended June 29, Precision BioSciences Inc.’s quick ratio stood at 2.60, while its current ratio was 2.60, showing that the company is able to pay off its debt. Based on annual data, DTIL earned $125.46 million in gross profit and brought in $25.1 million in revenue.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. DTIL’s revenue rose 80.7% to $8.78 million during the quarter, while net income inched up to $19.79 million. While analysts expected Precision BioSciences Inc. to report -$0.24 quarterly earnings, the actual figure was -$0.1 per share, beating the consensus estimate by 58.30%. During the quarter, the company generated -$9.7 million in EBITDA. The liabilities of Precision BioSciences Inc. were 147.66 million at the end of its most recent quarter ended June 29, and its total debt was $27.99 million. The value of shareholders’ equity is $115.07 million.
Technical Picture
This quick technical analysis looks at Precision BioSciences Inc.’s (DTIL) price momentum. With a historical volatility rate of 37.85%, the RSI 9-day stood at 33.71% on 16 August.
With respect to its five-day moving average, the current Precision BioSciences Inc. price is down by -2.74% percent or -$0.0148. At present, DTIL shares trade -20.59% below its 20-day simple moving average and -29.03% percent below its 100-day simple moving average. However, the stock is currently trading approximately -35.19% below its SMA50 and -62.23% below its SMA200.
Stochastic coefficient K was 21.12% and Stochastic coefficient D was 15.99%, while ATR was 0.0474. Given the Stochastic reading of 39.57% for the 14-day period, the RSI (14) reading has been calculated as 37.23%.
Analyst Ratings
BMO Capital Markets launched its rating on Precision BioSciences Inc. (NASDAQ: DTIL) to an Outperform in a note to investors on June 17, 2022. Precision BioSciences Inc. (DTIL) has been rated Overweight by analysts. According to 0 brokerage firms, DTIL is a sell, and 2 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Precision BioSciences Inc. stock as buy, with 4 recommending it as overweight.
With a median target price of $3.00, the current consensus forecast for the stock is $1.00 – $5.00. Based on these forecasts, analysts predict Precision BioSciences Inc. (DTIL) will achieve an average price target of $2.90.
